University of Cincinnati

11/17/2026 | Press release | Distributed by Public on 11/17/2026 16:21

New guidelines recommend routine prostate cancer screening for men over 50

New guidelines recommend routine prostate cancer screening for men over 50

Cancer Center expert featured in Healthline article

2 minute read November 17, 2026 Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Print Story Like

The University of Cincinnati Cancer's Taylor Goodstein was featured in a Healthline article discussing new American Cancer Society (ACS) guidelines recommending prostate-specific antigen (PSA) screening every 2 years starting at age 50 for men at average risk, and annually starting at age 45 for those at higher risk, including Black men and men with a family history of prostate cancer.

This is the first time the ACS has updated guidelines since 2010, and research over that time has highlighted the importance and value in PSA screening.

"Prostate cancer can take many years, even decades, to become clinically significant, so it takes a long time for us to see the consequences of changes in screening practices," Goodstein, MD, assistant professor of urology in UC's College of Medicine , who wasn't involved in the report, told Healthline.

"With longer follow-up from randomized trials, we now have more convincing evidence that PSA screening reduces the risk of dying from prostate cancer," Goodstein continued. "If we screen men, we can catch troublesome cancers early, before they have a chance to spread."

Read the Healthline article.

Featured photo at top of a person holding a blood sample being tested for PSA. Photo/Kitsawet Saethao/iStock Photo.

Related Stories

1

New clinical trial aims to optimize pain management and reduce opioid use after mastectomy

March 7, 2025

MSN highlighted a new University of Cincinnati Cancer Center clinical trial aimed to optimize pain management and reduce the need for opioids after mastectomy procedures.

2

UC achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

May 13, 2026

Researchers at the University of Cincinnati Gardner Neuroscience Institute's Brain Tumor Center have been confirmed as the first in the world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment. The findings were published in Surgical Neurology International and recently featured in The Cancer Letter.

3

Understanding resistance to targeted therapies in head and neck, breast cancer

July 11, 2025

MSN highlighted University of Cincinnati Cancer Center and Cincinnati Veterans Affairs Medical Center research published in the journal Oncotarget that reviewed current research on why Epidermal Growth Factor Receptor-targeted therapies often fail in breast and head and neck cancers.

University of Cincinnati published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 22:22 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]